Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982960 | 0.78 | LIMK1 (0.61) | LIMK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4985387 | 0.76 | DRD2 (0.43) | LIMK1DRD2DRD4DRD3 | |
| SCHEMBL4989371 | 0.76 | LIMK1 (0.47) | LIMK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4988053 | 0.76 | ALDH1A1 (0.58) | LIMK1ALDH1A1DHFRDRD2DRD4 | |
| SCHEMBL4989502 | 0.76 | RAD52 (0.42) | LIMK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4986127 | 0.75 | LIMK1 (0.47) | LIMK1KDM4EALDH1A1 | |
| SCHEMBL4992362 | 0.74 | LIMK1 (0.48) | LIMK1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4985467 | 0.74 | LIMK1 (0.48) | LIMK1MEN1KMT2APARP1DHFR | |
| SCHEMBL13532587 | 0.74 | HSD11B1 (0.39) | MEN1KMT2A | |
| SCHEMBL4988948 | 0.74 | LIMK1 (0.43) | LIMK1MEN1KMT2APARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | LIMK1 1960/4885MEN1 4853/4885KMT2A 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.